Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases

Nagendra Sastri Yarla,1 Gopal Pathuri,1,2 Hariprasad Gali,2 Simon Terzyan,3 Janani Panneerselvam,1 Parthasarathy Chandrakesan,4 Marcus Tullius Scotti,5 Courtney Houchen,4 Venkateshwar Madka,1 Chinthalapally V Rao1,6 1Center for Cancer Prevention and Drug Development, Hem-Onc Section, Department of M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yarla NS, Pathuri G, Gali H, Terzyan S, Panneerselvam J, Chandrakesan P, Scotti MT, Houchen C, Madka V, Rao CV
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	mpges-1/5-lox dual inhibitor lfa-9 drug design anti-inflammatory agent cancer chemoprevention Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/d0e4a62c502b44d49fbfa05f23208b17
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d0e4a62c502b44d49fbfa05f23208b17
record_format	dspace
institution	DOAJ
collection	DOAJ
language	EN
topic	mpges-1/5-lox dual inhibitor lfa-9 drug design anti-inflammatory agent cancer chemoprevention Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	mpges-1/5-lox dual inhibitor lfa-9 drug design anti-inflammatory agent cancer chemoprevention Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Yarla NS Pathuri G Gali H Terzyan S Panneerselvam J Chandrakesan P Scotti MT Houchen C Madka V Rao CV Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases
description	Nagendra Sastri Yarla,1 Gopal Pathuri,1,2 Hariprasad Gali,2 Simon Terzyan,3 Janani Panneerselvam,1 Parthasarathy Chandrakesan,4 Marcus Tullius Scotti,5 Courtney Houchen,4 Venkateshwar Madka,1 Chinthalapally V Rao1,6 1Center for Cancer Prevention and Drug Development, Hem-Onc Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; 2College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; 3Laboratory of Biomolecular Structure and Function; Department of Biochemistry and Molecular Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; 4Division of Digestive Diseases and Nutrition, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; 5Laboratory of Cheminformatics, Program of Natural and Synthetic Bioactive Products (PgPNSB), Health Sciences Center, Federal University of Paraíba, João Pessoa, PB, Brazil; 6VA Medical Center, Oklahoma City, OK 73104, USACorrespondence: Chinthalapally V Rao Tel +1 405-271-3224Email CV-Rao@ouhsc.eduBackground: Non-steroidal anti-inflammatory drugs, cyclooxygenase (COX)-2 selective inhibitors, have been explored for prevention and treatment of several inflammatory chronic conditions including arthritis, and cancer. However, the long-term use of these drugs is associated with gastrointestinal, renal, and cardiovascular side effects. Later, COX/5-lipoxygenase (5-LOX) dual inhibitors (eg, licofelone) have been developed but did not enter into the market from the clinical trails due to COX-1/2 inhibition-associated side effects. Hence, targeting microsomal prostaglandin E synthase-1 (mPGES-1) and 5-LOX can be an ideal approach while sparing COX-1/2 activities for development of the next generation of anti-inflammatory drugs with better efficacy and safety.Materials and Methods: In silico (molecular modelling) studies were used to design a mPGES-1/5-LOX dual inhibitory and COX-1/2 sparing lead molecule licofelone analogue-9 (LFA-9) by modifying the pharmacophore of licofelone. In vitro cell-free enzymatic (mPGES-1, 5-LOX, COX-1/2) assays using fluorometric/colorimetric methods and cell-based assays (LPS-induced PGE2, LTB4, and PGI2 productions from macrophages) using ELISA technique, isothermal calorimetry, and circular dichroism techniques were performed to determine the mPGES-1/5-LOX inhibitory efficacy and selectivity. Anti-inflammatory efficacy of LFA-9 was evaluated using a carrageenan (inflammogen)-induced rat paw edema model. Infiltration/expression of CD68 immune cells and TNF-α in paw tissues were evaluated using confocal microscope and immunoblot analysis. Anti-cancer effect of LFA-9 was evaluated using colon spheroids in vitro.Results: LFA‐9 inhibited mPGES-1/5-LOX and their products PGE2 and LTB4, spared COX-1/2 and its product PGI2. LFA‐9 bound strongly with human mPGES‐1/5‐LOX enzymes and induced changes in their secondary structure, thereby inhibited their enzymatic activities. LFA-9 inhibited carrageenan-induced inflammation (70.4%) in rats and suppressed CD68 immune cell infiltration (P ≤ 0.0001) and TNF-α expression. LFA-9 suppressed colon tumor stemness (60.2%) in vitro through inhibition of PGE2 (82%) levels.Conclusion: Overall study results suggest that LFA-9 is a mPGES-1/5-LOX dual inhibitor and showed anti-inflammatory and colorectal cancer preventive activities, and warranted detailed studies.Keywords: mPGES-1/5-LOX dual inhibitor, LFA-9, drug design, anti-inflammatory agent, cancer chemoprevention
format	article
author	Yarla NS Pathuri G Gali H Terzyan S Panneerselvam J Chandrakesan P Scotti MT Houchen C Madka V Rao CV
author_facet	Yarla NS Pathuri G Gali H Terzyan S Panneerselvam J Chandrakesan P Scotti MT Houchen C Madka V Rao CV
author_sort	Yarla NS
title	Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases
title_short	Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases
title_full	Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases
title_fullStr	Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases
title_full_unstemmed	Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases
title_sort	discovery and development of a novel mpges-1/5-lox dual inhibitor lfa-9 for prevention and treatment of chronic inflammatory diseases
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/d0e4a62c502b44d49fbfa05f23208b17
work_keys_str_mv	AT yarlans discoveryanddevelopmentofanovelmpges15loxdualinhibitorlfa9forpreventionandtreatmentofchronicinflammatorydiseases AT pathurig discoveryanddevelopmentofanovelmpges15loxdualinhibitorlfa9forpreventionandtreatmentofchronicinflammatorydiseases AT galih discoveryanddevelopmentofanovelmpges15loxdualinhibitorlfa9forpreventionandtreatmentofchronicinflammatorydiseases AT terzyans discoveryanddevelopmentofanovelmpges15loxdualinhibitorlfa9forpreventionandtreatmentofchronicinflammatorydiseases AT panneerselvamj discoveryanddevelopmentofanovelmpges15loxdualinhibitorlfa9forpreventionandtreatmentofchronicinflammatorydiseases AT chandrakesanp discoveryanddevelopmentofanovelmpges15loxdualinhibitorlfa9forpreventionandtreatmentofchronicinflammatorydiseases AT scottimt discoveryanddevelopmentofanovelmpges15loxdualinhibitorlfa9forpreventionandtreatmentofchronicinflammatorydiseases AT houchenc discoveryanddevelopmentofanovelmpges15loxdualinhibitorlfa9forpreventionandtreatmentofchronicinflammatorydiseases AT madkav discoveryanddevelopmentofanovelmpges15loxdualinhibitorlfa9forpreventionandtreatmentofchronicinflammatorydiseases AT raocv discoveryanddevelopmentofanovelmpges15loxdualinhibitorlfa9forpreventionandtreatmentofchronicinflammatorydiseases
_version_	1718388611630497792
spelling	oai:doaj.org-article:d0e4a62c502b44d49fbfa05f23208b172021-12-02T15:06:09ZDiscovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases1178-7031https://doaj.org/article/d0e4a62c502b44d49fbfa05f23208b172020-12-01T00:00:00Zhttps://www.dovepress.com/discovery-and-development-of-a-novel-mpges-15-lox-dual-inhibitor-lfa-9-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Nagendra Sastri Yarla,1 Gopal Pathuri,1,2 Hariprasad Gali,2 Simon Terzyan,3 Janani Panneerselvam,1 Parthasarathy Chandrakesan,4 Marcus Tullius Scotti,5 Courtney Houchen,4 Venkateshwar Madka,1 Chinthalapally V Rao1,6 1Center for Cancer Prevention and Drug Development, Hem-Onc Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; 2College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; 3Laboratory of Biomolecular Structure and Function; Department of Biochemistry and Molecular Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; 4Division of Digestive Diseases and Nutrition, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; 5Laboratory of Cheminformatics, Program of Natural and Synthetic Bioactive Products (PgPNSB), Health Sciences Center, Federal University of Paraíba, João Pessoa, PB, Brazil; 6VA Medical Center, Oklahoma City, OK 73104, USACorrespondence: Chinthalapally V Rao Tel +1 405-271-3224Email CV-Rao@ouhsc.eduBackground: Non-steroidal anti-inflammatory drugs, cyclooxygenase (COX)-2 selective inhibitors, have been explored for prevention and treatment of several inflammatory chronic conditions including arthritis, and cancer. However, the long-term use of these drugs is associated with gastrointestinal, renal, and cardiovascular side effects. Later, COX/5-lipoxygenase (5-LOX) dual inhibitors (eg, licofelone) have been developed but did not enter into the market from the clinical trails due to COX-1/2 inhibition-associated side effects. Hence, targeting microsomal prostaglandin E synthase-1 (mPGES-1) and 5-LOX can be an ideal approach while sparing COX-1/2 activities for development of the next generation of anti-inflammatory drugs with better efficacy and safety.Materials and Methods: In silico (molecular modelling) studies were used to design a mPGES-1/5-LOX dual inhibitory and COX-1/2 sparing lead molecule licofelone analogue-9 (LFA-9) by modifying the pharmacophore of licofelone. In vitro cell-free enzymatic (mPGES-1, 5-LOX, COX-1/2) assays using fluorometric/colorimetric methods and cell-based assays (LPS-induced PGE2, LTB4, and PGI2 productions from macrophages) using ELISA technique, isothermal calorimetry, and circular dichroism techniques were performed to determine the mPGES-1/5-LOX inhibitory efficacy and selectivity. Anti-inflammatory efficacy of LFA-9 was evaluated using a carrageenan (inflammogen)-induced rat paw edema model. Infiltration/expression of CD68 immune cells and TNF-α in paw tissues were evaluated using confocal microscope and immunoblot analysis. Anti-cancer effect of LFA-9 was evaluated using colon spheroids in vitro.Results: LFA‐9 inhibited mPGES-1/5-LOX and their products PGE2 and LTB4, spared COX-1/2 and its product PGI2. LFA‐9 bound strongly with human mPGES‐1/5‐LOX enzymes and induced changes in their secondary structure, thereby inhibited their enzymatic activities. LFA-9 inhibited carrageenan-induced inflammation (70.4%) in rats and suppressed CD68 immune cell infiltration (P ≤ 0.0001) and TNF-α expression. LFA-9 suppressed colon tumor stemness (60.2%) in vitro through inhibition of PGE2 (82%) levels.Conclusion: Overall study results suggest that LFA-9 is a mPGES-1/5-LOX dual inhibitor and showed anti-inflammatory and colorectal cancer preventive activities, and warranted detailed studies.Keywords: mPGES-1/5-LOX dual inhibitor, LFA-9, drug design, anti-inflammatory agent, cancer chemopreventionYarla NSPathuri GGali HTerzyan SPanneerselvam JChandrakesan PScotti MTHouchen CMadka VRao CVDove Medical Pressarticlempges-1/5-lox dual inhibitorlfa-9drug designanti-inflammatory agentcancer chemopreventionPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 13, Pp 1261-1278 (2020)

Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases

Ejemplares similares